MedCity News April 8, 2024
Frank Vinluan

The CAR T-therapies Abecma and Carvykti may now be used in earlier lines of treatment for multiple myeloma. The expanded FDA approvals makes these cell therapies more accessible to more patients, broadening the market for both products.

Relapse is common in multiple myeloma, and when it happens, a drug that worked for a patient before might no longer help. Two cell therapies already approved for this cancer may now be used in earlier lines of treatment, a regulatory decision that brings additional choices for patients who have exhausted standard multiple myeloma treatment options.

Multiple myeloma is a blood cancer that develops in the plasma cells in bone marrow. The expanded FDA approvals announced Friday cover Abecma, from Bristol Myers Squibb...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma / Biotech
Related Articles:
Building Resilience: CDMO Strategies for Drug Supply Chain Stability
Metsera’s IPO Raises $275M to Show How Its Obesity Drugs Can Top Current GLP-1s
STAT+: How Trump’s tariffs may raise health care costs, from medical devices to prescription drugs
One Institution’s Evidence-Based Approach to Adopting Biosimilars
Cell and Gene Therapies — Improving Access and Outcomes for Medicare and Medicaid Beneficiaries

Share This Article